PROGRAM DESCRIPTION
Molluscum contagiosum is a common skin infection in children caused by a poxvirus that appears as one or as many as dozens of small, smooth, pink, white, or flesh-colored bumps, called mollusca. Current treatment options include surgical removal or scraping of the mollusca, topical acids or creams that dissolve the mollusca, injectable medications, and oral cimetidine. Though none of these options are currently FDA approved for treatment of molluscum contagiosum, there are 2 topical therapies under investigation. Managed care pharmacists should be familiar with both of these pipeline therapy options and associated clinical data as a treatment for this disease could significantly improve quality of life for pediatric patients with the disease.
EDUCATIONAL OBJECTIVES
At the completion of this activity, participants will be able to:
- Review the epidemiology, pathophysiology, clinical presentation, and health-related quality of life for patients with molluscum contagiosum
- Analyze the latest data on the efficacy, safety, and adminstration of emerging treatments for molluscum contagiosum
- Examine the role of managed care professionals in the development of evidence-based clinical protocols for molluscum contagiosum
Pharmacy Times Continuing Education™ is
accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy
education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number
0290-0000-21-157-L01-P. The activity is available for CE credit through September 6, 2021.